Generic Name and Formulations:
Cosyntropin 0.25mg/mL; pwd for IV or IM inj after reconstitution; preservative-free.
Amphastar Pharmaceuticals, Inc.
Indications for CORTROSYN:
For use in the screening of patients presumed to have adrenocortical insufficiency.
Adults and Children:
Give by IV, IM inj or IV infusion over 4–8hrs. <2yrs: 0.125mg. ≥2yrs: Usual range: 0.25–0.75mg.
Patients with raised bilirubin or where plasma contains free hemoglobin: falsely high fluorescence measurements may result. Pregnancy (Cat.C). Nursing mothers.
May accentuate the electrolyte loss associated with diuretics. May exhibit abnormally high plasma cortisol levels if patients taking cortisone, hydrocortisone, spironolactone, estrogens.
Hypersensitivity reactions (eg, rare, but possible), bradycardia, tachycardia, hypertension, peripheral edema, rash.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed